Abstracts tagged "juvenile idiopathic arthritis (JIA) and systemic lupus erythematosus (SLE)"

Abstract Number: 2013 • 2012 ACR/ARHP Annual Meeting
Cross-Sectional and Longitudinal comparison of Bone Mass Status, Using pQCT, in a Large Cohort of Juvenile Idiopathic Arthritis and Juvenile Onset Systemic Lupus Erythematosus Patients
Fernanda Falcini¹, Stefano Stagi², Loredana Cavalli³, Giulia Carnesecchi⁴, Federico Bertini⁴, Laura Masi³, Marco Matucci-Cerinic⁵ and Maria Luisa Brandi³, ¹Department of Biomedicine, Division of Rheumatology AOUC, Excellence Centre for Research, Florence, Italy, ²Pediatric Unit,, Mugello's Hospital, Borgo San Lorenzo, Firenze, Italy, ³Department of Internal Medicine, Endocrinology Unit, University of Florence, Firenze, Italy, ⁴Department of Internal Medicine, Rheumatology Section, University of Florence, Florence, Italy, ⁵Medicine, Univ Florence, Firenze, Italy
Background/Purpose: A small number of prospective data have been published on the use of pQCT in large groups of pts with JIA and JSLE. Moreover,…
Abstract Number: 2014 • 2012 ACR/ARHP Annual Meeting
Serum 25(OH)D Levels in Adolescents and Young Adults with Juvenile Idiopathic Arthritis and Juvenile Onset Systemic Lupus Erythematosus: Prevalence and Association with Disease Activity
Fernanda Falcini¹, Stefano Stagi², Loredana Cavalli³, Giulia Carnesecchi¹, Federico Bertini¹, Laura Masi³, Marco Matucci-Cerinic¹ and Maria Luisa Brandi³, ¹Department of Internal Medicine, Rheumatology Section, Transition Clinic, University of Florence, Florence, Italy, ²Pediatric Endocrinology Unit, Anna Meyer Children’s Hospital, University of Florence, Firenze, Italy, ³Department of Internal Medicine, Endocrinology Unit, University of Florence, Firenze, Italy
Background/Purpose: Numerous data are available in literature on 25 (OH)D serum levels in general population, few and contradictory in Juvenile Idiopathic Arthritis (JIA), and scarce…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].